<DOC>
	<DOCNO>NCT03004521</DOCNO>
	<brief_summary>LQD multicentre randomise clinical trial compare clinical cost effectiveness lithium versus quetiapine use add-on therapy antidepressant medication patient treatment resistant depression . The Lithium versus Quetiapine Depression ( LQD ) study assess patient 12 month establish ( ) treatment likely improve TRD long duration time . Professor Anthony Cleare Chief Investigator recruitment due start November 2016 . Recruitment begin London , follow additional site Newcastle Oxford early 2017 .</brief_summary>
	<brief_title>Lithium Versus Quetiapine Treatment Resistant Depression</brief_title>
	<detailed_description>This 12 month parallel group , multi-centre , patient randomise , pragmatic , open label trial compare clinical cost-effectiveness decision prescribe lithium versus quetiapine add-on treatment antidepressant medication . There two parallel group : 1 ) Quetiapine add-on exist antidepressant medication ; 2 ) Lithium add-on exist antidepressant medication . 276 patient randomise 1:1 baseline decision prescribe either lithium quetiapine , treatment undertaken clinician real world basis . The acute phase treatment ( 8 week post-randomisation ) conduct trial clinician decision continue treatment per standard care thereafter . All patient , regardless treatment status , follow trial one year . This superiority design whereby hypothesise quetiapine superior lithium term time treatment discontinuation average symptom burden ( QID-SR ) 12 month .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depressive Disorder , Treatment-Resistant</mesh_term>
	<mesh_term>Lithium Carbonate</mesh_term>
	<mesh_term>Antidepressive Agents</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<criteria>1 . Under care GP and/or adult mental health service 2 . Current episode depression meeting DSM5 criterion major depressive disorder ( MDD ) single recurrent episode 3.17item HAMD score ≥ 14 cutoff reflect pragmatic minimum severity depression also choose comparable study STAR*D ( Rush et al 2006 , Trivedi et al 2006 ) 4.Any gender age 18 year 5.Meet criterion treatment resistant depression ( Fekadu et al. , 2009a ; Cleare et al. , 2015 ) : current episode respond least two antidepressant give least 6 week minimum therapeutic dose define fluoxetine ≥20mg/day , paroxetine ≥20mg/day , sertraline ≥50mg/day , citalopram ≥20mg/day , escitalopram ≥10mg/day , venlafaxine ≥75mg/day , duloxetine ≥60 mg/day , mirtazapine ≥30mg/day , tricyclic antidepressant ≥125mg/day , dosage guide national Maudsley Prescribing Guidelines BNF antidepressant . Please note , relapse whilst antidepressant also count fail treatment trial 6.Current antidepressant treatment remain unchanged ≥6 week 7.Provision write , informed consent . 1 . Diagnosis bipolar disorder ( defined meeting DSM5 criterion bipolar 1 bipolar 2 ) MINI 7.0 ( recommended treatment different bipolar depression ) 2 . Diagnosis current psychosis ( recommended treatment different current psychosis antidepressant plus antipsychotic firstline treatment recommendation ( NiCE , 2009 ; Cleare et al. , 2015 ) 3 . Use lithium quetiapine current episode 4 . Ongoing use another atypical antipsychotic ( discontinuation require study entry i.e . time prior randomisation ) 5 . Known contraindication use either lithium quetiapine : know hypersensitivity lithium quetiapine excipients ; severe renal insufficiency / impairment ; untreated hypothyroidism ; severe cardiac disease / insufficiency ; low sodium level e.g . dehydrated patient low sodium diet ; Addison 's disease ; Brugada syndrome family history Brugada syndrome ; rare hereditary inborn error metabolism galactosaemia , Lapp lactase deficiency glucosegalactose malabsorption ; concomitant administration cytochrome P450 3A4 inhibitor ; previously diagnose QT prolongation . 6 . We recruit individual currently participate clinical trial investigational medical product ( CTIMP ) . 7 . Insufficient degree comprehension attention able engage trial procedure . 8 . We exclude woman pregnant , actively try pregnancy , currently breastfeed . This base verbal report subject . Otherwise management appropriate accord standard clinical practice within context pragmatic , open trial , example adequate contraceptive precaution decide clinical judgement prescriber .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Lithium</keyword>
	<keyword>Quetiapine</keyword>
	<keyword>Augmentation</keyword>
</DOC>